Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study

Abstract

received from Genentech, Bristol-Myers Squibb, and Pfizer; and ownership interest with Tetralogic Pharmaceuticals. Reviewer "A" discloses no financial relationships. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. On the basis of disclosed information, all conflicts of interest have been resolved. LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe prognostic factors in metastatic colorectal cancer. 2. Estimate prognostic score with a simple model using only PS and LDH as parameters.This article is available for continuing medical education credit at CME.TheOncologist.com. The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. CME CME Gastrointestinal CancerThe Oncologist 2011;16:1228 -1238 www.TheOncologist.com ABSTRACTBackground. The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer. Patients and Methods. Eight hundred three patients treated with FOLFOX or FOLFIRI in three prospective trials were randomly separated into learning (n ‫؍‬ 535) and validation (n ‫؍‬ 268) samples. Eleven baseline variables were evaluated in univariate and multivariate analysis as prognostic factors for overall survival, and a prognostic score was developed.Results. Independent prognostic factors identified in multivariate analysis for overall survival were performance status (PS) (p < .001), serum lactate dehydrogenase (LDH) (p < .001), and number of metastatic sites (p ‫؍‬ .005). A prognostic score based on these three vari-

Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma

“…Another limitation of our study is the absence of PAL recording in the "cohort set-2." Nevertheless, we did not observe any association between PAL and Ang-2 in the "cohort set-1" Moreover, the GERCOR analysis, performed on 803 patients mCRC treated by FOLFOX or FOLFIRI in the first-line setting demonstrated that LDH, number of metastatic sites, and PS were the only independent prognostic factors (24).…”

“…However, the GERCOR score displayed a better discriminative ability (C ¼ 0.64) than the Kohne model (C ¼ 0.55; ref. 24). We then used the GERCOR model as the reference score.…”

“…Another score usually chosen is the Kohne score, based on the performance status (PS), white blood cell count, number of metastatic sites, and alkaline phosphatase level (23). More recently, the simplified score of the Groupe Coop erateur Multidisciplinaire en Oncologie GERCOR offered a convenient fashion to investigate mCRC patient's prognosis, by monitoring PS and lactate dehydrogenase (LDH) status and exhibited a better discrimination ability (24). Using these two parameters, the GERCOR score could identify three distinct groups of patients with mCRC according to their risk of death: A low-risk group (median OS ¼ 29.8 months), an intermediaterisk group (median OS ¼ 19.5 months), and a high-risk group (median OS ¼ 13.9 months).…”

Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer

“…A variety of baseline laboratory data were evaluated in prospective chemotherapy studies and found to predict treatment outcome including: elevated lactate dehydrogenase (LDH) (14,15), white blood cell J Gastrointest Oncol 2017;8(1):70-80 jgo.amegroups.com Table 3 Summary of significant differences in the reporting of all grades and severe (CTCAE grade ≥3) all-causality adverse events over day 0-90 from first RE procedure in A.…”

Factors associated with the efficiency of maintenance therapy in patients with metastatic colorectal cancer

“…Наибольшее время без ХТ было отмечено в группе пациентов с хорошим соматическим статусом (ECOG -0-1), низким уровнем лактатдегидрогеназы (ЛДГ) и щелочной фосфатазы (≤ 3 верхним границам нормы), небольшой распространенностью опухолевого процесса (≤ 1 органа, пораженного метастазами) [2]. Отметим, что в качестве факторов неблагоприят-ного прогноза при совокупном анализе данных 3 ис-следований -OPTIMOX1 (сравнение схемы FOLFOX4 до прогрессирования и интермитирующей ХТ по схеме FOLFOX7) [3], OPTIMOX2 и C97-3 (схемы FOLFIRI в 1-й линии и FOLFOX6 во 2-й против обратной по-следовательности) -были выделены следующие при-знаки неблагоприятного прогноза: низкий соматичес-кий статус (ECOG 2), высокий уровень ЛДГ (> 1 верхней границы нормы), поражение метастазами > 1 органа [4]. Также при анализе исследований OPTIMOX1 и OPTI-MOX2 было выявлено, что пациенты с нормальным уровнем РЭА выигрывали от «ХТ-каникул» по сравне-нию с больными, которым продолжали ХТ до прогрес-сирования [5].…”